Holen Sie sich die Stockscreener-App
2.11
5.50%
0.11
Handel nachbörslich:
2.05
-0.06
-2.84%
Schlusskurs vom Vortag:
$2.00
Offen:
$2.07
24-Stunden-Volumen:
30,865
Relative Volume:
0.99
Marktkapitalisierung:
$37.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.91M
KGV:
-11.49
EPS:
-0.1837
Netto-Cashflow:
-
1W Leistung:
-28.23%
1M Leistung:
-10.59%
6M Leistung:
-15.60%
1J Leistung:
+134.44%
1-Tages-Spanne:
$2.0509
$2.1672
1-Wochen-Bereich:
$2.00
$3.1199
52-Wochen-Spanne:
$0.8501
$12.68
Incannex Healthcare Inc Stock (IXHL) Company Profile
Vergleichen Sie IXHL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IXHL | 2.11 | 37.40M | 0 | -21.91M | 0 | -0.1837 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Incannex Healthcare Inc (IXHL) Quarterly 10-Q Report - Quartzy
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Incannex Secures $59M Financing, Reports Q1 Results Amid Clinical Trial Progress | IXHL Stock News - StockTitan
Incannex Healthcare names Lou Barbato as chief medical officer - MSN
Incannex appoints new chief medical officer - Investing.com India
Incannex appoints new chief medical officer By Investing.com - Investing.com South Africa
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewswire
Incannex Healthcare Appoints Dr. Barbato as CMO - TipRanks
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks - Simply Wall St
Incannex Healthcare secures $3.3 million through debt financing By Investing.com - Investing.com Australia
Incannex Healthcare secures $3.3 million through debt financing - Investing.com
Incannex Healthcare secures A$6.9 million funding By Investing.com - Investing.com Australia
Incannex Healthcare secures A$6.9 million funding - Investing.com
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials - Sleep Review
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Invezz
R&D tax breaks buoy Incannex as losses narrow - Green Market Report
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Growth in Short Interest - Defense World
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - The Manila Times
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat
Incannex Secures Up to $60M in Financing to Support Clinical Trials - Sleep Review
Incannex secures financing deal valued at US$60 million - Mugglehead
Incannex $60 Million Deal With Arena For Late-Stage Drug TrialsIncannex Healthcare (NASDAQ:IXHL) - Benzinga
Incannex Healthcare secures $60 million funding via equity and debt - Investing.com
Incannex Healthcare secures $60 million funding via equity and debt By Investing.com - Investing.com UK
Incannex Healthcare lands $60 million financing deal - Green Market Report
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors - GlobeNewswire
Incannex secures $60 million in funding for clinical trials - Investing.com
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest - MarketBeat
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Virtu Financial LLC Buys New Shares in Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
4 Psychedelic Stocks to Consider as Clinical Trials Heat up - Investing.com
FDA Review of PsiGAD2 IND complete; clinical trial for - GlobeNewswire
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety - Benzinga
Incannex Healthcare gets FDA nod for Phase 2 trial - Green Market Report
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - StockTitan
Tidal Investments LLC Buys New Stake in Incannex Healthcare Inc. (NASDAQ:IXHL) - MarketBeat
Tidal Investments LLC Acquires Shares of 423,410 Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewswire
Head to Head Review: Zai Lab (NASDAQ:ZLAB) vs. Incannex Healthcare (NASDAQ:IXHL) - Defense World
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Down 69.0% in June - MarketBeat
Finanzdaten der Incannex Healthcare Inc-Aktie (IXHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):